ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

atirmociclib

Also written as “PF-07220060 + PF-07104091 combination dose escalation”, “PF-07220060” and “Atirmociclib”.

In Pfizer’s pipeline, CDK4 inhibitor. Its studies are mostly in Breast Neoplasms · Liposarcoma · Hepatic Insufficiency, led by 4 companies.

Drug pageAtirmociclib: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 11, 202417 company-led studies, 10 open or runningNext primary completion: Feb 26, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only147 open or runningphase 3since Dec 11, 2024Sep 15, 2020Feb 26, 2027phase 2 · NCT05262400
AstraZenecaits history only11 open or runningphase 2since Feb 16, 2026Feb 16, 2026Dec 28, 2027phase 2 · NCT07427394
Hoffmann-La Roche11 open or runningphase 2since Jan 30, 2018Jan 30, 2018Sep 30, 2030phase 2 · NCT03424005
Olema Pharmaceuticalsits history only11 open or runningphase 1since Aug 16, 2022Aug 16, 2022Dec 31, 2027phase 1 · NCT05508906
  • Named in Pfizer’s own pipeline as atirmociclib PF-07220060, phase 3, as of Nov 3, 2026 (source).

Also a collaborator on its studies: Gilead Sciences, Arvinas Estrogen Receptor and Novartis.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 30, 2018First study: phase 2 study in Breast NeoplasmsFirst studyNCT03424005 · 1,132 planned · United States, Australia, France and more
  2. Aug 11, 2024Named atirmociclibINNProposed as its International Nonproprietary Name in WHO's List 131 · before, PF-07220060

Ahead

  1. Sep 30, 2030Primary completion: phase 2 study in Breast NeoplasmsNCT03424005

TargetBeta

“CDK4 inhibitor”the company's pipeline, read by Claude · source
“An orally bioavailable inhibitor of cyclin-dependent kinase 4 (CDK4), with potential antineoplastic activity. Upon administration, atirmociclib selectively inhibits CDK4, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase tran…”NCIt, read by Claude
“An orally bioavailable inhibitor of cyclin-dependent kinase 4 (CDK4), ”NCIt, by rule

Other programs on CDK4

ProgramCompanyFurthest phaseStudies
abemaciclibruleEli Lillyphase 449
palbociclibrulePfizerphase 436
trilaciclibrulePharmacosmosphase 414
culmerciclibSino Biopharmaceuticalphase 311
HRS-6209Jiangsu HengRui Medicinephase 37
CDK4 Inhibitor BGB-43395ruleBeOne Medicinesphase 34
narazaciclibrulehangzhou-hanx-biopharmaceuticals-ltdphase 24
vustanaciclibregor-pharmaceuticals-incphase 23
CG-7321rulechengdu-cynogen-bio-pharmaceutical-tech-co-ltdphase 11
nkt5097 cdk2rulenikang-therapeutics-incphase 11
TSL2109ruleChina Resources Pharmaceutical Groupphase 11

Studies

The one study Hoffmann-La Roche leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03424005Breast Neoplasms · United States, Australia, France and more2RecruitingSep 30, 20301,132

How it is read

Names in the registry

  • “PF-07220060 + PF-07104091 combination dose escalation”, 8 entries
  • “PF-07220060”, 7 entries
  • “Atirmociclib”, 5 entries
  • “PF-07104091 + PF-07220060 + fulvestrant dose expansion”, 2 entries
  • “Single dose of PF-07220060 as first Tablet Formulation”, 2 entries

Codes read as this program: PF07220060.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.